SCHEMBL2179710

SCHEMBL2179710

C=CC[C@@H](C[C@H](NC(=O)OC(C)(C)C)C(=O)O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.44
GRIK2 Q13002 2/20 0.44
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
KMT2A Q03164 1/20 0.43
CTSK P43235 6/20 0.43
CTSS P25774 4/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
PPARA Q07869 6/20 0.41
PPARG P37231 5/20 0.41
ACE P12821 1/20 0.40
PPARD Q03181 2/20 0.39
MAPT P10636 1/20 0.39
CAPN1 P07384 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13571099 1.00 GRIK1 (0.44) GRIK1GRIK2FNTAFNTBMEN1
SCHEMBL29273137 1.00 GRIK1 (0.44) GRIK1GRIK2FNTAFNTBMEN1
SCHEMBL7359050 0.87 MEN1 (0.46) MEN1GAAKMT2ACTSKCTSS
SCHEMBL212772 0.86 CTSK (0.47) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL2728681 0.86 CTSK (0.47) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL212773 0.86 CTSK (0.47) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL1890772 0.83 SMN1; SMN2 (0.44) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL12963013 0.82 SMN1; SMN2 (0.44) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL30965306 0.82 SMN1; SMN2 (0.44) CTSKCTSSCTSLCTSBSMN1; SMN2
SCHEMBL1128594 0.82 SMN1; SMN2 (0.44) CTSKCTSSCTSLCTSBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9308282-B2 [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation PIRAMAL IMAGING SA (CH) 2016-04-12 US disclosed
US-9238631-B2 Radiolabeled amino acids for diagnostic imaging PIRAMAL IMAGING SA (CH) 2016-01-19 US disclosed
US-20150011773-A1 RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING PIRAMAL IMAGING SA (CH) 2015-01-08 US disclosed
US-20140154183-A1 NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION LIFE MOLECULAR IMAGING SA (CH) 2014-06-05 US disclosed
US-20130149243-A1 METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 US disclosed
US-20130034497-A1 IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES PIRAMAL IMAGING SA (CH) 2013-02-07 US disclosed
EP-2520556-A1 Radiolabeled amino acids for diagnostic imaging Bayer Pharma Aktiengesellschaft (DE) 2012-11-07 EP disclosed
EP-2501663-A2 METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES Piramal Imaging SA (CH) 2012-09-26 EP disclosed
US-20110165076-A1 NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-07 US disclosed
US-20100290991-A1 NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION BAYER SCHERING PHARMA AG (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130149243-A1 METHOD FOR PRODUCTION OF F-18 LABELED GLUTAMIC ACID DERIVATIVES GLUL, SLC18A2, SLC1A2 GRIK1 46/4885GRIK2 19/4885FNTA 140/4885
US-20150011773-A1 RADIOLABELED AMINO ACIDS FOR DIAGNOSTIC IMAGING SLC1A5, SLC6A19, BCAT2 GRIK1 2290/4885GRIK2 2502/4885FNTA 511/4885
US-20100290991-A1 NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION GLUL, QPCT, SLC1A2 GRIK1 40/4885GRIK2 37/4885FNTA 354/4885
US-20130034497-A1 IODINE-LABELED HOMOGLUTAMIC ACID AND GLUTAMIC ACID DERIVATIVES GLUL, GCG, GLS GRIK1 28/4885GRIK2 34/4885FNTA 444/4885
US-20140154183-A1 NOVEL [F-18]-LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), THEIR USE AND PROCESSES FOR THEIR PREPARATION GLUL, QPCT, SLC1A2 GRIK1 40/4885GRIK2 37/4885FNTA 354/4885
US-20110165076-A1 NOVEL [F-18]- LABELLED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVES (I), USE THEREOF AND METHOD FOR THEIR PRODUCTION GLUL, QPCT, GFPT1 GRIK1 42/4885GRIK2 39/4885FNTA 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.